Potential beneficial effect of some adipokines positively correlated with the adipose tissue content on the cardiovascular system

International Journal of Cardiology

Volumn 222, Issue , 2016, Pages 581-589

  Sawicka, Magdalena ^a   Janowska, Joanna ^a   Chudek, Jerzy ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Adipokines; Angiogenesis; Endothelial progenitor cells; Epicardial adipose tissue; Heart failure; Obesity paradox

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOPOIETIN RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; APELIN; CHEMERIN; CTRP 3 PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 8; LEPTIN; MACROPHAGE MIGRATION INHIBITION FACTOR; MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN BETA; N(G),N(G) DIMETHYLARGININE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NITRIC OXIDE; OMENTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROGRANULIN; REACTIVE OXYGEN METABOLITE; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR GATA 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASPIN;

ADIPOSE TISSUE; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CARDIAC MUSCLE CELL; CARDIOPLEGIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CYTOKINE PRODUCTION; ENDOTHELIAL PROGENITOR CELL; HEART AFTERLOAD; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; OBESITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; REVIEW; TISSUE REGENERATION; VASODILATATION; ANIMAL; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DRUG EFFECTS; METABOLISM; TREATMENT OUTCOME;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; TREATMENT OUTCOME;

EID: 84982786854     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.07.054     Document Type: Review

References (152)

1. [1] Piepoli, M.F., Dimopoulos, K., Concu, A., Crisafulli, A., Cardiovascular and ventilatory control during exercise in chronic heart failure: role of muscle reflexes. Int. J. Cardiol. 130:1 (2008), 3–10.
2. [2] Yoshida, M., Ma, J., Tomita, T., et al. Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure. Congest. Heart Fail. 11 (2005), 12–16.
3. [3] McKie, P.M., Schirger, J.A., Costello-Boerrigter, L.C., et al. Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. J. Am. Coll. Cardiol., 58(20), 2011, 10.1016/j.jacc.2011.07.042.
4. [4] Piepoli, M.F., Crisafulli, A., Pathophysiology of human heart failure: importance of skeletal muscle myopathy and reflexes. Exp. Physiol. 99 (2014), 609–615.
5. [5] Ebong, I.A., Goff, D.C., Rodriguez, C.J., et al. The relationship between measures of obesity and incident heart failure: the multi-ethnic study of atherosclerosis. Obesity (Silver Spring) 21:9 (2013), 1915–1922.
6. [6] Pal, D., Dasgupta, S., Kundu, R., et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat. Med. 18 (2012), 1279–1285.
7. [7] Sun, J., Luo, J., Ruan, Y., et al. Free fatty acids activate renin-angiotensin system in 3T3-L1 adipocytes through nuclear factor-kappa B pathway. J. Diabetes Res., 2016, 2016, 1587594.
8. [8] Lohmeier, T.E., Iliescu, R., Tudorancea, I., et al. Chronic interactions between carotid baroreceptors and chemoreceptors in obesity hypertension. Hypertension, 2016 (HYPERTENSIONAHA.116.07232).
9. [9] Van Gaal, L.F., Mertens, I.L., De Block, C.E., Mechanisms linking obesity with cardiovascular disease. Nature 444 (2006), 875–880.
10. [10] Wang, H.-T., Liu, C.-F., Tsai, T.-H., et al. Effect of obesity reduction on preservation of heart function and attenuation of left ventricular remodeling, oxidative stress and inflammation in obese mice. J. Transl. Med., 10, 2012, 145.
11. [11] Huang, H., Amin, V., Gurin, M., et al. Diet-induced obesity causes long QT and reduces transcription of voltage-gated potassium channels. J. Mol. Cell. Cardiol. 59 (2013), 151–158.
12. [12] Hookana, E., Juntilla, M.J., Puurunen, V.P., et al. Causes of nonischemic sudden cardiac death in the current era. Heart Rhythm. 8:10 (2011), 1570–1575.
13. [13] Horwich, T.B., Fonarow, G.C., Hamilton, M.A., MacLellan, W.R., Woo, M.A., Tillisch, J.A., The relationship between obesity and mortality in patients with heart failure. J. Am. Coll. Cardiol. 78:3 (2001), 789–795.
14. [14] Lavie, C.L., Alpert, M.A., Arena, R., Mehra, M.R., Milani, R.V., Ventura, H.O., Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail. 1:2 (2013), 93–102.
15. [15] Ouchi, N., Kobayashi, H., Kihara, S., et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J. Biol. Chem. 279:2 (2004), 1304–1309.
16. [16] Maruyama, S., Shibata, R., Kikuchi, R., et al. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. J. Biol. Chem. 287:1 (2012), 408–417.
17. [17] Arita, Y., Kihara, S., Ouchi, N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257:1 (1999 Apr 2), 79–83.
18. [18] de Souza Batista, C.M., Yang, R.Z., Lee, M.J., et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56:6 (2007 Jun), 1655–1661.
19. [19] Rega-Kaun, G., Kaun, C., Wojta, J., More than a simple storage organ: adipose tissue as a source of adipokines involved in cardiovascular disease. Thromb. Haemost. 110:4 (Oct 2013), 641–650.
20. [20] Zaitone, S.A., Abo-Gresha, N.M., Rosuvastatin promotes angiogenesis and reverses isoproterenol-induced acute myocardial infarction in rats: Role of iNOS and VEGF. European Journal of Pharmacology 691:1–3 (2012 Sep 15), 134–142.
21. [21] Post, S., Peeters, W., Busser, E., et al. Balance between Angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvessel density. J. Vasc. Res. 45 (2008), 244–250.
22. [22] Chong, A.Y., Caine, G.J., Freestone, B., Blann, A.D., Lip, G.Y., Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure. J. Am. Coll. Cardiol. 43:3 (Feb 4 2004), 423–428.
23. [23] Chen, S., Guo, L., Chen, B., Sun, L., Cui, M., Association of serum angiopoietin-1, angiopoietin-2 and angiopoietin-2 to angiopoietin-1 ratio with heart failure in patients with acute myocardial infarction. Exp. Ther. Med. 5:3 (2013), 937–941.
24. [24] Han, X., Liu, L., Niu, J., Yang, J., Zhang, Z., Zhang, Z., Serum VEGF predicts worse clinical outcome of patients with coronary heart disease after percutaneous coronary intervention therapy. Med. Sci. Monit. 21 (Oct 26 2015), 3247–3251.
25. [25] Kodde, I.F., van der Stok, J., Smolenski, R.T., de Jong, J.W., Metabolic and genetic regulation of cardiac energy substrate preference. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 146:1 (2007), 26–39.
26. [26] Djouadi, F., Brandt, J., Weinheimer, C.J. et al., The role of the peroxisome proliferator-activated receptor α (PPARα) in the control of cardiac lipid metabolism. Prostagl Leukot Essent Fatty Acids 60 (1999), 339–343.
27. [27] Sack, M.N., Rader, T.A., Park, S., Bastin, J., McCune, S.A., Kelly, D.P., Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94 (1996), 2837–2842.
28. [28] Sharma, S., Adrogue, J.V., Golfman, L., et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 18:14 (2004), 1692–1700.
29. [29] Simon, J.N., Chowdhury, S.A.K., Warren, C.M., et al. Ceramide-mediated depression in cardiomyocyte contractility through PKC activation and modulation of myofilament protein phosphorylation. Basic Res. Cardiol., 109, 2014, 445.
30. [30] Drosatos, K., Bharadwaj, K.G., Lymperopoulos, A., et al. Cardiomyocyte lipids impair β-adrenergic receptor function via PKC activation. Am. J. Physiol. Endocrinol. Metab. 300:3 (2011), E489–E499.
31. [31] Miller, T.A., LeBrasseur, N.K., Cote, G.M., et al. Oleate prevents palmitate-induced cytotoxic stress in cardiac myocytes. Biochem. Biophys. Res. Commun. 336 (2005), 309–315.
32. [32] Borradaile, N.M., Han, X., Harp, J.D., et al. Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. J. Lipid Res. 47:12 (2006), 2726–2737.
33. [33] Tchkonia, T., Thomou, T., Zhu, Y., et al. Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab. 17:5 (2013), 644–656.
34. [34] Shirani, J., Berezowski, K., Roberts, W.C., Quantitative measurement of normal and excessive (cor adiposum) subepicardial adipose tissue, its clinical significance, and its effect on electrocardiographic QRS voltage. Am. J. Cardiol. 76:5 (1995), 414–418.
35. [35] Khawaja, T., Greer, C., Chokshi, A., et al. Fat volume in patients with left ventricular systolic dysfunction. Am. J. Cardiol. 108:3 (2011), 397–401.
36. [36] Fitzgibbons, T.P., Czech, M.P., Epicardial and perivascular adipose tissues and their influence on cardiovascular disease: basic mechanisms and clinical associations. J. Am. Heart Assoc., 3(2), 2014, e000582.
37. [37] Sacks, H.S., Fain, J.N., Holman, B., et al. Uncoupling protein-1 and related messenger ribonucleic acids in human epicardial and other adipose tissues: epicardial fat functioning as brown fat. J. Clin. Endocrinol. Metab. 94:9 (2009), 3611–3615.
38. [38] Marchington, J.M., Mattacks, C.A., Pond, C.M., Adipose tissue in the mammalian heart and pericardium: structure, foetal development and biochemical properties. Comp. Biochem. Physiol. B 94:2 (1989), 225–232.
39. [39] Crendal, E., Dutheil, F., Naughton, G., et al. Increased myocardial dysfunction, dyssynchrony, and epicardial fat across the lifespan in healthy males. BMC Cardiovasc. Disord., 14, 2014, 95.
40. [40] Mookadam, F., Goel, R., Alharthi, M.S., et al. Epicardial fat and its association with cardiovascular risk: a cross-sectional observational study. Heart Views 11:3 (2010), 103–108.
41. [41] Ueno, K., Anzai, T., Jinzaki, M., et al. Increased epicardial fat volume quantified by 64-multidetector computed tomography is associated with coronary atherosclerosis and totally occlusive lesions. Circ. J. 73:10 (2009), 1927–1933.
42. [42] Eroglu, S., Sade, L.E., Yildirir, A., et al. Epicardial adipose tissue thickness by echocardiography is a marker for the presence and severity of coronary artery disease. Nutr. Metab. Cardiovasc. Dis. 19:3 (2009), 211–217.
43. [43] Asahara, T., Murohara, T., Sullivan, A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:5302 (1997), 964–967.
44. [44] Beltrami, A.P., Barlucchi, L., Torella, D., et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114:6 (2003), 763–776.
45. 2 sensing. Science 292:5516 (2001), 464–468.
46. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Biol. Sci. Biochem. 95:14 (1998), 7987–7992.
47. [47] Lando, D., Peet, D.J., Gorman, J.J., et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16:12 (2002), 1466–1471.
48. [48] Shweiki, D., Itin, A., Soffer, D., Keshet, E., Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:6398 (29 1992), 843–845.
49. [49] Ceradini, D.J., Kulkarni, A.R., Callaghan, M.J., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10 (2004), 858–864.
50. [50] Skuli, N., Liu, L., Runge, A., et al. Endothelial deletion of hypoxia-inducible factor–2α (HIF-2α) alters vascular function and tumor angiogenesis. Blood 114:2 (2009), 469–477.
51. [51] Heineke, J., Auger-Messier, M., Xu, J., et al. Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart. J. Clin. Invest. 117:11 (2007), 3198–3210.
52. [52] Ferrara, N., Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25 (2004), 581–611.
53. [53] Koblizek, T.I., Weiss, C., Yancopoulos, G.D., et al. Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr. Biol. 8:9 (1998), 529–532.
54. [54] Gale, N.W., Thurston, G., Hackett, S.F., et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev. Cell 3:3 (2002), 411–423.
55. [55] Murakami, M., Nguyen, L.T., Zhang, Z.W., et al. The FGF system has a key role in regulating vascular integrity. J. Clin. Invest. 118:10 (2008), 3355–3366.
56. [56] Yamada, Y., Takakura, N., Yasue, H., et al. Exogenous clustered neuropilin 1 enhances vasculogenesis and angiogenesis. Blood 97:6 (2001), 1671–1678.
57. [57] Corada, M., Nyqvist, D., Orsenigo, F., et al. The Wnt/beta-catenin pathway modulates vascular remodeling and specification by upregulating Dll4/notch signaling. Dev. Cell 18:6 (2010), 938–949.
58. [58] Benedito, R., Roca, C., Sörensen, I., et al. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 137:61 (2009), 1124–1135.
59. [59] Phng, L.K., Potente, M., Leslie, J.D., et al. Nrarp coordinates endothelial notch and Wnt signaling to control vessel density in angiogenesis. Dev. Cell 16:1 (2009), 70–82.
60. [60] Sun, Z., Li, X., Massena, S., et al. VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd. J. Exp. Med. 209 (2012), 1363–1377.
61. [61] Gerhardt, H., Golding, M., Fruttiger, M., et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161 (2003), 1163–1177.
62. [62] Hellström, M., Phng, L.-K., Hofmann, J.J., et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445 (2007), 776–780.
63. [63] Ruhrberg, C., Gerhardt, H., Golding, M., et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev. 16 (2002), 2684–2698.
64. [64] Vlodavsky, I., Folkman, J., Sullivan, R., et al. Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc. Natl. Acad. Sci. U. S. A. 84:8 (1987), 2292–2296.
65. [65] Felcht, M., Luck, R., Schering, A., et al. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J. Clin. Invest. 122:6 (2012), 1991–2005.
66. [66] Strilić, B., Kučera, T., Eglinger, J., et al. The molecular basis of vascular lumen formation in the developing mouse aorta. Dev. Cell 17:4 (2009), 505–515.
67. [67] Li, S., Zhou, X.L., Dang, Y.Y., et al. Basal Flt1 tyrosine kinase activity is a positive regulator of endothelial survival and vascularization during zebrafish embryogenesis. Biochim. Biophys. Acta Gen. Subj. 1850:2 (2015), 373–384.
68. [68] Murakami, M., Nguyen, L.T., Zhuang, Z.W., et al. The FGF system has a key role in regulating vascular integrity. J. Clin. Invest. 118:10 (2008), 3355–3366 (Erratum in: J Clin Invest 2009 Jul;119(7):2113. Zhang, Zhen W [corrected to Zhuang, Zhen W]).
69. [69] Saharinen, P., Eklund, L., Miettinen, J., et al. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell–cell and cell-matrix contacts. Nat. Cell Biol. 10:5 (2008), 527–537.
70. [70] Hellstrom, M., Kalen, M., Lindahl, P., Abramsson, A., Betsholtz, C., Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126 (1999), 3047–3055.
71. [71] Fraccarollo, D., Widder, J.D., Galuppo, P., et al. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 118:8 (19 2008), 818–827.
72. [72] Kanzler, I., Tuchscheerer, N., Steffens, G., et al. Differential roles of angiogenic chemokines in endothelial progenitor cell-induced angiogenesis. Basic Res. Cardiol., 108(1), 2013, 310.
73. [73] Grisar, J.C., Haddad, F., Gomari, F.A., Wu, J.C., Endothelial progenitor cells in cardiovascular disease and chronic inflammation: from biomarker to therapeutic agent. Biomark. Med 5:6 (2011), 731–744.
74. [74] Durik, M., Sevá Pessôa, B., Roks, A.J.M., The renin–angiotensin system, bone marrow and progenitor cells. Clin. Sci. (Lond.) 123 (2012), 205–223.
75. [75] Chan, KH, Simpson, P.J.L., Yong, A.S., et al. The relationship between endothelial progenitor cell populations and epicardial and microvascular coronary disease—a cellular, angiographic and physiologic study. Germain S, ed. PLoS ONE, 9(4), 2014, e93980.
76. [76] Tatemoto, K., Hosoya, M., Habata, Y., et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem. Biophys. Res. Commun. 251:(2) 20 (1998), 471–476.
77. [77] Japp, A.G., Cruden, N.L., Amer, D.A.B., et al. Vascular effects of apelin in vivo in man. J. Am. Coll. Cardiol. 52:11 (2008), 908–913.
78. [78] Japp, A.G., Cruden, N.L., Barnes, G., et al. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation 121 (2010), 1818–1827.
79. [79] Szokodi, I., Tavi, P., Földes, G., et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ. Res. 91 (2002), 434–440.
80. [80] Alfarano, C., Foussal, C., Lairez, O., et al. Transition from metabolic adaptation to maladaptation of the heart in obesity: role of apelin. Int. J. Obes. 39:2 (2015), 312–320.
81. [81] Pisarenko, O.I., Lankin, V.Z., Konovalova, G.G., et al. Apelin-12 and its structural analog enhance antioxidant defense in experimental myocardial ischemia and reperfusion. Mol. Cell. Biochem. 391:1 (2014), 241–250.
82. [82] Li, L., Zeng, H., Chen, J.-X., Apelin-13 increases myocardial progenitor cells and improves repair postmyocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 303:5 (2012), H605–H618.
83. [83] Zeng, H., He, X., Hou, X., et al. Apelin gene therapy increases myocardial vascular density and ameliorates diabetic cardiomyopathy via upregulation of sirtuin 3. Am. J. Physiol. Heart Circ. Physiol. 306:4 (2014), H585–H597.
84. [84] Sato, T., Suzuki, T., Watanabe, H., et al. Apelin is a positive regulator of ACE2 in failing hearts. J. Clin. Invest. 123:12 (2013), 5203–5211.
85. [85] Leeper, N.J., Tedesco, M.M., Kojima, Y., et al. Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. Am. J. Physiol. Heart Circ. Physiol. 296:5 (2009), 1329–1335.
86. [86] Yao, F., Lv, Y.-C., Zhang, M., et al. Apelin-13 impedes foam cell formation by activating Class III PI3K/Beclin-1-mediated autophagic pathway. Biochem. Biophys. Res. Commun. 466:(4)4 (2015), 637–643.
87. [87] Chong, K.S., Gardner, R.S., Morton, J.J., Ashley, E.A., McDonagh, T.A., Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 8 (2006), 355–360.
88. [88] Jung, C.H., Lee, W.J., Hwang, J.Y., et al. Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through aphosphatidylinositol 3-kinase/Akt pathway. Biochem. Biophys. Res. Commun. 23:413(2) (2011), 264–269.
89. [89] Jung, C.H., Lee, M.J., Kang, Y.M., et al. Vaspin inhibits cytokine-induced nuclear factor-kappa B activation and adhesion molecule expression via AMP-activated protein kinase activation in vascular endothelial cells. Cardiovasc. Diabetol., 13, 2014, 41.
90. [90] Sun, N., Wang, H., Wang, L., Vaspin alleviates dysfunction of endothelial progenitor cells induced by high glucose via PI3K/Akt/eNOS pathway. Int. J. Clin. Exp. Pathol. 8:1 (2015), 482–489.
91. [91] Jung, C.H., Lee, W.J., Hwang, J.Y., et al. Vaspin increases nitric oxide bioavailability through the reduction of asymmetric dimethylarginine in vascular endothelial cells. Grundmann S, ed PLoS ONE, 7(12), 2012, e52346.
92. [92] Zhang, B., Peng, W., Li, H., et al. Plasma vaspin concentrations are decreased in acute coronary syndrome, but unchanged in patients without coronary lesions. Clin. Biochem. 46:15 (2013), 1520–1525.
93. [93] Kawase, R., Ohama, T., Matsuyama, A., et al. Deletion of progranulin exacerbates atherosclerosis in ApoE knockout mice. Cardiovasc. Res. 100:1 (2013), 125–133.
94. [94] Hwang, H.-J., Jung, T.W., Hong, H.C., et al. Progranulin protects vascular endothelium against atherosclerotic inflammatory reaction via Akt/eNOS and nuclear factor-κB pathways. Mohanraj R, ed PLoS ONE, 8(9), 2013, e76679.
95. [95] Tang, W., Lu, Y., Tian, Q.-Y., et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 332:6028 (2011), 478–484.
96. [96] Matsubara, T., Mita, A., Minami, K., et al. PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metab. 15:1 (2012), 38–50.
97. [97] Kessenbrock, K., Fröhlich, L., Sixt, M., et al. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. J. Clin. Invest. 118:7 (2008), 2438–2447.
98. [98] Zabel, B.A., Allen, S.J., Kulig, P., et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J. Biol. Chem., 280, 2005, 34661-.
99. [99] Ji, Q., Lin, Y., Liang, Z., et al. Chemerin is a novel biomarker of acute coronary syndrome but not of stable angina pectoris. Cardiovasc. Diabetol., 13, 2014, 145.
100. ATP channel opener iptakalim. Acta Pharmacol. Sin. 32:5 (2011), 573–580.
101. [101] Bozaoglu, K., Curran, J.E., Stocker, C.J., et al. Chemerin, a novel adipokine in the regulation of angiogenesis. J. Clin. Endocrinol. Metab. 95:5 (2010), 2476–2485.
102. [102] Cash, J.L., Hart, R., Russ, A., et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J. Exp. Med. 205:4 (2008), 767–775.
103. [103] Wong, G.W., Krawczyk, S.A., Kitidis-Mitrokostas, C., Revett, T., Gimeno, R., Lodish, H.F., Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-γ agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochem. J. 416:2 (2008), 161–177.
104. [104] Yi, W., Sun, Y., Yuan, Y., et al. C1q/TNF-related protein-3, a newly identified adipokine, is a novel anti-apoptotic, pro-angiogenic, and cardioprotective molecule in the ischemic mouse heart. Circulation 125:25 (2012), 3159–3169.
105. [105] Romacho, T., Villalobos, L.A., Cercas, E., et al. Visfatin as a novel mediator released by inflamed human endothelial cells. Song Q, ed PLoS ONE, 8(10), 2013, e78283.
106. [106] Romacho, T., Sánchez-Ferrer, C.F., Peiró, C., Visfatin/Nampt: an adipokine with cardiovascular impact. Mediat. Inflamm., 2013, 2013, 946427.
107. [107] Hsu, C.P., Oka, S., Shao, D., et al. Nicotinamide phosphoribosyltransferase regulates cell survival through NAD + synthesis in cardiac myocytes. Circ. Res. 105:5 (2009), 481–491.
108. [108] Wang, P., Xu, T.Y., Guan, Y.F., Su, D.F., Fan, G.R., Miao, C.Y., Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc. Res. 81:2 (2009), 370–380.
109. [109] Moschen, A.R., Kaser, A., Enrich, B., et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 178 (2007), 1748–1758.
110. [110] Dahl, T.B., Yndestad, A., Skjelland, M., et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115:8 (2007), 972–980.
111. [111] Liu, S.W., Qiao, S.B., Yuan, J.S., Liu, D.Q., Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin. Endocrinol. 71:2 (2009), 202–207.
112. [112] Huang, Q., Guo, Y., Zeng, H., et al. Visfatin stimulates a cellular renin-angiotensin system in cultured rat mesangial cells. Endocr. Res. 36:3 (2011), 93–100.
113. [113] Lovren, F., Pan, Y., Shukla, P.C., et al. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. Am. J. Physiol. Endocrinol. Metab. 296:6 (2009), E1440–E1449.
114. [114] Kim, S.R., Jung, Y.H., Park, H.J., et al. Upregulation of thromboxane synthase mediates visfatin-induced interleukin-8 expression and angiogenic activity in endothelial cells. Biochem. Biophys. Res. Commun. 24:418(4) (2012), 662–668.
115. [115] Adya, R., Tan, B.K., Punn, A., et al. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc. Res. 78:2 (2008), 356–365.
116. [116] Bae, Y.H., Bae, M.K., Kim, S.R., et al. Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis. Biochem. Biophys. Res. Commun. 379:2 (2009), 206–211.
117. [117] Lim, S.Y., Davidson, S.M., Paramanathan, A.J., et al. The novel adipocytokine visfatin exerts direct cardioprotective effects. J. Cell. Mol. Med. 12:4 (2008), 1395–1403.
118. [118] Bulló, M., García-Lorda, P., Megias, I., Salas-Salvadó, J., Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes. Res. 11 (2003), 525–531.
119. [119] Singh, P., Peterson, T.E., Barber, K.R., et al. Leptin upregulates the expression of plasminogen activator inhibitor-1 in human vascular endothelial cells. Biochem. Biophys. Res. Commun. 392:1 (2010), 47–52.
120. [120] Söderberg, S., Ahrén, B., Jansson, J.H., et al. Leptin is associated with increased risk of myocardial infarction. J. Intern. Med. 246:4 (1999), 409–418.
121. [121] Bouloumié, A., Marumo, T., Lafontan, M., et al. Leptin induces oxidative stress in human endothelial cells. FASEB J. 13:10 (1999), 1231–1238.
122. [122] Park, H.Y., Kwon, H.M., Lim, H.J., et al. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp. Mol. Med. 30:33(2) (2001), 95–102.
123. [123] Considine, R.V., Sinha, M.K., Heiman, M.L., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 1:334(5) (1996), 292–295.
124. [124] McGaffin, K.R., Moravec, C.S., McTiernan, C.F., Leptin signaling in the failing and mechanically unloaded human heart. Circ. Heart Fail. 2:6 (2009), 676–683.
125. [125] McGaffin, K.R., Sun, C.K., Rager, J.J., et al. Leptin signalling reduces the severity of cardiac dysfunction and remodelling after chronic ischaemic injury. Cardiovasc. Res. 77:1 (2008), 54–63.
126. [126] Cao, R., Brakenhielm, E., Wahlestedt, C., et al. Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc. Natl. Acad. Sci. U. S. A. 98:11 (2001), 6390–6395.
127. [127] Garonna, E., Botham, K.M., Birdsey, G.M., Randi, A.M., Gonzalez-Perez, R.R., Wheeler-Jones, C.P.D., Vascular endothelial growth factor receptor-2 couples Cyclo-oxygenase-2 with pro-angiogenic actions of leptin on human endothelial cells. Agarwal S, ed PLoS ONE, 6(4), 2011, e18823.
128. [128] Schroeter, M.R., Stein, S., Heida, N.M., et al. Leptin promotes the mobilization of vascular progenitor cells and neovascularization by NOX2-mediated activation of MMP9. Cardiovasc. Res. 93:1 (2012), 170–180.
129. [129] Vecchione, C., Maffei, A., Colella, S., et al. Leptin effect on endothelial nitric oxide is mediated through Akt–endothelial nitric oxide synthase phosphorylation pathway. Diabetes 51:1 (2002), 168–173.
130. [130] Matsuda, K., Teragawa, H., Fukuda, Y., et al. Leptin causes nitric-oxide independent coronary artery vasodilation in humans. Hypertens. Res. 26:2 (2003), 147–152.
131. [131] Rodríguez, A., Gómez-Ambrosi, J., Catalán, V., et al. Leptin inhibits the proliferation of vascular smooth muscle cells induced by angiotensin II through nitric oxide-dependent mechanisms. Mediat. Inflamm., 2010, 2010, 105489.
132. [132] Atkinson, L.L., Fischer, M.A., Lopaschuk, G.D., Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis. J. Biol. Chem. 277:33 (2002), 29424–29430.
133. [133] Hintz, K.K., Aberle, N.S., Ren, J., Insulin resistance induces hyperleptinemia, cardiac contractile dysfunction but not cardiac leptin resistance in ventricular myocytes. Int. J. Obes. Relat. Metab. Disord. 27:10 (2003), 1196–1203.
134. [134] Rajapurohitam, V., Gan, X.T., Kirshenbaum, L.A., Karmazyn, M., The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ. Res. 93:4 (2003), 277–279.
135. [135] Heida, N.-M., Leifheit-Nestler, M., Schroeter, M.R., et al. Leptin enhances the potency of circulating angiogenic cells via Src kinase and integrin αvβ5: implications for angiogenesis in human obesity. Arterioscler. Thromb. Vasc. Biol. 30:2 (2010), 200–206.
136. [136] Kern, P.A., Saghizadeh, M., Ong, J.M., Bosch, R.J., Deem, R., Simsolo, R.B., The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss and relationship to lipoprotein lipase. J. Clin. Invest. 95:5 (1995), 2111–2119.
137. [137] Pober, J.S., Effects of tumour necrosis factor and related cytokines on vascular endothelial cells. CIBA Found. Symp. 131 (1987), 170–184.
138. [138] Tartaglia, L.A., Goeddel, D.V., Two TNF receptors. Immunol. Today 13:5 (1992), 151–153.
139. [139] Hsu, H., Xiong, J., Goeddel, D.V., The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell 81:4 (1995), 495–504.
140. [140] Vandenabeele, P., Declercq, W., Beyaert, R., Fiers, W., Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 5:10 (1995), 392–399.
141. [141] Luo, Y., Xu, Z., Wan, T., et al. Endothelial-specific transgenesis of TNFR2 promotes adaptive arteriogenesis and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 30:7 (2010), 1307–1314.
142. [142] Higuchi, Y., McTiernan, C.F., Frye, C.B., McGowan, B.S., Chan, T.O., Feldman, A.M., Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-α–induced cardiomyopathy. Circulation 109 (2004), 1892–1897.
143. [143] Aggarwal, S., Gollapudi, S., Gupta, S., Increased TNF-alpha-induced apoptosis in lymphocytes from aged humans: changes in TNF-alpha receptor expression and activation of caspases. J. Immunol. 162:4 (15 1999), 2154–2161.
144. + cardiac stem cells in ischemic heart disease. Stem Cells 31:9 (2013), 1881–1892.
145. [145] Meldrum, D.R., Dinarello, C.A., Cleveland, J.C. Jr., et al. Hydrogen peroxide induces tumor necrosis factor alpha-mediated cardiac injury by a P38 mitogen-activated protein kinase-dependent mechanism. Surgery 124:2 (1998), 291–297.
146. [146] Herse, F., Fain, J.N., Janke, J., et al. Adipose tissue-derived soluble fms-like tyrosine kinase 1 is an obesity-relevant endogenous paracrine adipokine. Hypertension 58:1 (2011), 37–42.
147. [147] Brame, A.L., Maguire, J.J., Yang, P., et al. Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. Hypertension 65:4 (2015), 834–840.
148. [148] Iturrioz, X., Alvear-Perez, R., De Mota, N., et al. Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist. FASEB J. 24:5 (2010), 1506–1517.
149. [149] Azizi, Y., Faghihi, M., Imani, A., et al. Post-infarct treatment with [Pyr1]apelin-13 improves myocardial function by increasing neovascularization and overexpression of angiogenic growth factors in rats. Eur. J. Pharmacol. 15:761 (2015), 101–108.
150. [150] Pisarenko, O.I., Shulzhenko, V.S., Pelogeykina, Y.A., et al. Enhancement of crystalloid cardioplegic protection by structural analogs of apelin-12. J. Surg. Res. 194:1 (2015), 18–24.
151. [151] Liu, C., Li, X.-X., Gao, W., et al. Progranulin-derived Atsttrin directly binds to TNFRSF25 (DR3) and inhibits TNF-like ligand 1A (TL1A) activity. Ryffel B, ed PloS ONE, 9(3), 2014, e92743.
152. [152] Mann, D.L., McMurray, J.J.V., Packer, M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004), 1594–1602.